Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercial traction while multiple pipeline data readouts remain on track for H2 2026, RBC Capital said in a Monday note.

According to the note, Casgevy's Q2 revenue rose to $76 million on broader market adoption, though the therapy remains unprofitable as RBC awaits progress in the company's in vivo gene-editing programs.

RBC said H2 2026 is expected to bring several pipeline readouts, including the phase Ia data for the ANG3 program, the phase II results from the factor XI siRNA collaboration with Sirius Therapeutics, and phase I updates for the company's allogeneic CAR-T programs.

Meanwhile, RBC analysts said Crispr ended the quarter with about $2.4 billion in cash and lower-than-expected operating expenses but remains cautious on its ex vivo gene-editing programs as Casgevy has yet to reach profitability despite pipeline diversification into siRNA.

RBC maintained its sector perform rating on the stock with a $50 price target.

Crispr Therapeutics shares were up more than 3% in Tuesday trading.

Price: 51.33, Change: +1.76, Percent Change: +3.55